Wall Street analysts expect that AstraZeneca plc (NYSE:AZN) will report sales of $5.76 billion for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for AstraZeneca’s earnings, with the lowest sales estimate coming in at $5.37 billion and the highest estimate coming in at $6.12 billion. AstraZeneca reported sales of $5.59 billion during the same quarter last year, which indicates a positive year over year growth rate of 3%. The firm is scheduled to issue its next earnings results on Thursday, February 1st.
According to Zacks, analysts expect that AstraZeneca will report full-year sales of $5.76 billion for the current fiscal year, with estimates ranging from $20.03 billion to $22.48 billion. For the next fiscal year, analysts anticipate that the business will report sales of $22.07 billion per share, with estimates ranging from $20.47 billion to $23.93 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that cover AstraZeneca.
AstraZeneca (NYSE:AZN) last announced its quarterly earnings results on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.55. The firm had revenue of $6.23 billion for the quarter, compared to the consensus estimate of $6 billion. AstraZeneca had a return on equity of 34.02% and a net margin of 15.90%. The business’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.32 earnings per share.
A number of brokerages have weighed in on AZN. BMO Capital Markets set a $38.00 price target on AstraZeneca and gave the stock a “buy” rating in a research report on Wednesday, November 15th. Leerink Swann boosted their price target on AstraZeneca from $31.00 to $34.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. Citigroup raised AstraZeneca to a “buy” rating in a research report on Wednesday, October 18th. Cowen reissued a “hold” rating and set a $37.00 price target on shares of AstraZeneca in a research report on Tuesday, October 17th. Finally, Credit Suisse Group raised AstraZeneca from a “neutral” rating to an “outperform” rating in a research report on Monday, October 16th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $34.20.
Several institutional investors have recently bought and sold shares of the company. Fisher Asset Management LLC grew its position in shares of AstraZeneca by 4.7% in the third quarter. Fisher Asset Management LLC now owns 11,601,573 shares of the company’s stock valued at $393,061,000 after purchasing an additional 519,717 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of AstraZeneca by 7.6% in the third quarter. Wells Fargo & Company MN now owns 4,406,824 shares of the company’s stock valued at $149,303,000 after purchasing an additional 310,389 shares during the last quarter. Ameriprise Financial Inc. grew its position in shares of AstraZeneca by 7.1% in the third quarter. Ameriprise Financial Inc. now owns 3,026,781 shares of the company’s stock valued at $102,643,000 after purchasing an additional 199,519 shares during the last quarter. Capital Bank & Trust Co grew its position in shares of AstraZeneca by 2.1% in the third quarter. Capital Bank & Trust Co now owns 2,730,208 shares of the company’s stock valued at $92,499,000 after purchasing an additional 57,353 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of AstraZeneca by 18.3% in the third quarter. Dimensional Fund Advisors LP now owns 2,558,882 shares of the company’s stock valued at $86,695,000 after purchasing an additional 395,699 shares during the last quarter. 14.75% of the stock is currently owned by institutional investors.
Shares of AstraZeneca (AZN) traded up $0.39 during midday trading on Thursday, reaching $34.11. The company’s stock had a trading volume of 2,441,142 shares, compared to its average volume of 2,640,000. The firm has a market capitalization of $84,690.00, a P/E ratio of 24.36, a PEG ratio of 3.06 and a beta of 0.76. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 1.09. AstraZeneca has a 1 year low of $26.51 and a 1 year high of $35.60.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.